FDA warning is not behind reduced use of anemia meds, study finds

08/15/2013 | Washington Post (tiered subscription model), The

The "black box" warning issued by the FDA in 2007 doesn't seem to be the reason behind the reduced use of erythropoiesis-stimulating agents to treat anemia in dialysis patients, according to a study in the journal BMC Nephrology. Instead, a change in Medicare payments appears to be behind the steady decline.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Briefs: